EE91 Economic Evaluation of Durvalumab for the Treatment of Patients With Stage III Unresectable Locally Advanced Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Platinum-Based Chemoradiation Therapy
Abstract
Authors
R Rubio Ponce M Naranjo